Multivariable logistic regression analyses confirmed that infliximab, compared with adalimumab, smoking, inflammatory disease (B1) in patients with Crohn's disease and anti‐TNF therapy without an immunomodulator, but not dosing regimen or diagnosis, were independently associated with the development of immunogenicity to first anti‐TNF (Figure 2; Figures S1 and S2). Here, TNF is linked to Crohn disease.